Slowed Movement Stopping in Parkinson's Disease and Focal Dystonia is Improved by Standard Treatment

Sci Rep. 2019 Dec 20;9(1):19504. doi: 10.1038/s41598-019-55321-5.

Abstract

Patients with Parkinson's disease and focal dystonia have difficulty in generating and preventing movement. Reaction time (RT) and stop signal reaction time (SSRT) measure the speed to initiate and stop a movement respectively. We developed a portable device to assess RT and SSRT. This incorporated a novel analysis to measure SSRT more efficiently (optimal combination SSRT, ocSSRT). After validation ocSSRT was measured in Parkinson's disease patients without dyskinesia (PD), cervical dystonia (CD) and writer's cramp. We also assessed how ocSSRT responded to L-dopa in PD patients and botulinum toxin injections in CD patients. Participants were instructed to release a button following a green LED flash on the device. On 25% of trials, a red LED flashed 5-195 ms after the green LED; participations were instructed to abort the button release on these trials. ocSSRT and RT were significantly prolonged in patients with Parkinson's disease and focal dystonia (one-way ANOVA p < 0.001). Administration of L-dopa significantly improved ocSSRT and RT in PD patients (p < 0.001). Administration of botulinum toxin significantly improved ocSSRT, but not RT, in CD patients (p < 0.05). ocSSRT is an easily-administered bedside neuro-physiological tool; significantly prolonged ocSSRT is associated with PD and focal dystonia.

Publication types

  • Clinical Trial
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Botulinum Toxins / therapeutic use*
  • Dystonic Disorders / drug therapy*
  • Dystonic Disorders / physiopathology*
  • Humans
  • Levodopa / therapeutic use
  • Movement / drug effects*
  • Movement / physiology*
  • Parkinson Disease / drug therapy*
  • Parkinson Disease / physiopathology*

Substances

  • Levodopa
  • Botulinum Toxins